The global biosimilar monoclonal antibodies market was valued at US$ 1,516.9 Mn in 2016 and is projected to reach US$ 32,015.0 Mn in 2026 at a CAGR of 35.7% from 2017 to 2026. By drug class: Adalimumab segment is estimated to register highest CAGR of over 37.7%, thereby accounting for highest revenue share among the drug class segments. By application: Oncology segment is estimated to account for highest revenue share among the application segments, and register highest CAGR of over 38.0% over the forecast period. By region: Revenue from the market in Asia Pacific is expected to expand at a highest CAGR of over 36.9% over the forecast period.
Score from the experts at Killer Infographics
Visual Communication - 55%
Design - 55%
Content/Script - 50%
Usability - 60%
While the content is kept short here throughout, which is good, it's visually a bit difficult to determine the subject of this infographic. Additionally, many of the statistics don't contain the full numbers, making it hard to get the most value from the info. We'd give this an F.